Gantenerumab by F. Hoffmann-La Roche for Alzheimer’s Disease: Likelihood of Approval

Gantenerumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 9% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn. GlobalData’s report assesses how Gantenerumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gantenerumab overview

Gantenerumab (RG-1450, RO-4909832) is under development for the treatment and prevention of Alzheimer’s disease (AD). It is administered through subcutaneous route. The drug candidate is a fully human HuCAL monoclonal antibody that acts by targeting amyloid-beta peptide (amyloid precursor protein). It is developed based on human combinatorial antibody library (HuCAL) fab technology.

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

For a complete picture of Gantenerumab’s drug-specific PTSR and LoA scores, buy the report here.